Theme

Vaccines and medicines against COVID-19

Read about the current studies and development of vaccines and medicines for treatment of COVID-19, and how medicines can be approved much quicker in extraordinary situations, if patient safety is sufficiently assured.

Go to theme

News and notifications

EMA to undertake a review of data as to the AstraZeneca vaccine’s efficacy in preventing COVID-19 disease

15 April 2021

The European Medicines Agency (EMA) is undertaking a review of vaccination data of the COVID-19 vaccine from AstraZeneca. The review will include infection rates, hospitalisations, morbidity and mortality. The EMA will also prepare a recommendation for those who have received the first dose of the vaccine.

EMA: The AstraZeneca vaccine possibly causes rare, serious symptoms – but remains authorised for use

08 April 2021

COVID-19 Vaccine AstraZeneca: Investigations of blood clots with low numbers of platelets and bleeding continue in Denmark and in the EU

26 March 2021

Status on the drug regulatory authorities’ investigation of blood clots after vaccination with the AstraZeneca vaccine

18 March 2021